Spots Global Cancer Trial Database for primary myelofibrosis
Every month we try and update this database with for primary myelofibrosis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy | NCT01428635 | Accelerated Pha... Blast Phase Chr... Chronic Phase C... Primary Myelofi... Thrombocytopeni... | Eltrombopag Ola... | 18 Years - | M.D. Anderson Cancer Center | |
| Myeloproliferative Neoplasms: an In-depth Case-control Study | NCT01831635 | Polycythemia Ve... Essential Throm... Primary Myelofi... | Methodological ... Methodological ... Methodological ... | 18 Years - | Queen's University, Belfast | |
| Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome | NCT00445744 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... de Novo Myelody... Essential Throm... Myelodysplastic... Polycythemia Ve... Previously Trea... Primary Myelofi... Recurrent Adult... Recurrent Child... Secondary Acute... Secondary Myelo... Secondary Myelo... Untreated Adult... Untreated Child... | cyclophosphamid... busulfan tacrolimus methotrexate cytogenetic ana... flow cytometry pharmacological... pharmacogenomic... peripheral bloo... allogeneic hema... | - 65 Years | Fred Hutchinson Cancer Center | |
| Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) | NCT01236638 | Primary Myelofi... Post-Polycythem... Post-Essential ... | Momelotinib | 18 Years - | Sierra Oncology LLC - a GSK company | |
| Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia | NCT00003619 | Chronic Myelopr... Leukemia Myelodysplastic... Thrombocytopeni... | filgrastim vitamin E busulfan cytarabine etoposide fludarabine pho... isotretinoin topotecan hydro... bone marrow abl... peripheral bloo... | 19 Years - 90 Years | National Cancer Institute (NCI) | |
| Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI) | NCT04942080 | Myeloproliferat... Essential Throm... Primary Myelofi... Primary Myelofi... | CALR allele bur... | 18 Years - | University Hospital, Angers | |
| Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis | NCT02528877 | Acute Myeloid L... Primary Myelofi... Primary Myelofi... Secondary Acute... Secondary Myelo... | Allogeneic Bone... Allogeneic Hema... Fludarabine Pho... Laboratory Biom... Melphalan Peripheral Bloo... Pharmacological... Ruxolitinib Pho... Sirolimus Tacrolimus | 18 Years - 75 Years | City of Hope Medical Center | |
| CD34 Selection Using the Automated CliniMACS Prodigy | NCT06047886 | AML ALL Lymphoid Malign... Myelodysplastic... CML Primary Myelofi... | Infusion of CD3... | 4 Weeks - 75 Years | University of Alabama at Birmingham | |
| Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation | NCT04339101 | Acute Leukemia Hematologic and... Myelodysplastic... Primary Myelofi... Secondary Myelo... | Fludarabine Itacitinib Adip... Melphalan Quality-of-Life... Questionnaire A... Sirolimus Tacrolimus | 18 Years - 75 Years | City of Hope Medical Center | |
| A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis | NCT03165734 | Primary Myelofi... Post-polycythem... Post-essential ... | Pacritinib Physician's Cho... | 18 Years - | CTI BioPharma | |
| Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia | NCT02055781 | Primary Myelofi... Post-polycythem... Post-essential ... | Pacritinib Best Available ... | 18 Years - | CTI BioPharma | |
| LBH589 (Panobinostat) for the Treatment of Myelofibrosis | NCT01298934 | Primary Myelofi... Polycythemia Ve... Post-Essential ... | LBH589 | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| A Phase 2 Study of RO7490677 In Participants With Myelofibrosis | NCT01981850 | Primary Myelofi... Polycythemia Ve... Post-Essential ... | RO7490677 Ruxolitinib | 18 Years - | Hoffmann-La Roche | |
| Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis | NCT01731951 | Primary Myelofi... Secondary Myelo... Myeloid Maligna... | Imetelstat | 18 Years - | Geron Corporation | |
| An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis | NCT01633372 | MPN (Myeloproli... | itacitinib | 18 Years - | Incyte Corporation | |
| Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis | NCT01969838 | Primary Myelofi... Post-Polycythem... Post-Essential ... | Momelotinib Ruxolitinib Placebo to matc... Placebo to matc... | 18 Years - | Sierra Oncology LLC - a GSK company | |
| Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition | NCT06218628 | Primary Myelofi... Post-polycythem... Post-essential ... Chronic Myelomo... Polycythemia Ve... Essential Throm... | Talazoparib pacritinib | 18 Years - | Fox Chase Cancer Center | |
| Anti-TGF-beta Therapy in Patients With Myelofibrosis | NCT01291784 | Myelofibrosis Primary Myelofi... Polycythemia Ve... Post-essential ... | monoclonal anti... | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis | NCT02805868 | Myelofibrosis Polycythemia Ve... Primary Myelofi... Thrombocytopeni... | Bone Marrow Asp... Laboratory Biom... Siltuximab | 18 Years - | Northwestern University | |
| Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005) | NCT05223920 | Thrombocythemia... Primary Myelofi... | Bomedemstat | 18 Years - | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | |
| Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients | NCT04243122 | Myeloproliferat... Essential Throm... JAK2 Mutation Polycythemia Ve... Primary Myelofi... Venous Thromboe... | Apixaban 2.5 MG... Aspirin 81 mg | 18 Years - | Ottawa Hospital Research Institute | |
| Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation | NCT00005641 | Chronic Myelopr... Graft Versus Ho... Leukemia Multiple Myelom... Myelodysplastic... | anti-thymocyte ... busulfan cyclophosphamid... cyclosporine leucovorin calc... methotrexate methylprednisol... allogeneic bone... in vitro-treate... radiation thera... | 15 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome | NCT00445744 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... de Novo Myelody... Essential Throm... Myelodysplastic... Polycythemia Ve... Previously Trea... Primary Myelofi... Recurrent Adult... Recurrent Child... Secondary Acute... Secondary Myelo... Secondary Myelo... Untreated Adult... Untreated Child... | cyclophosphamid... busulfan tacrolimus methotrexate cytogenetic ana... flow cytometry pharmacological... pharmacogenomic... peripheral bloo... allogeneic hema... | - 65 Years | Fred Hutchinson Cancer Center | |
| Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib | NCT02226172 | Primary Myelofi... | Glasdegib (PF-0... Placebo | 18 Years - | Pfizer | |
| CC-4047 in Treating Patients With Myelofibrosis | NCT00669578 | Chronic Myelopr... Secondary Myelo... | CC-4047 | 18 Years - 120 Years | Mayo Clinic | |
| A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib | NCT03755518 | Primary Myelofi... Post-Polycythem... Myelofibrosis Post-essential ... | FEDRATINIB | 18 Years - | Celgene | |
| Myeloproliferative Neoplastic Diseases Observatory From Brest | NCT02897297 | Polycythemia Ve... Essential Throm... Primary Myelofi... | - | University Hospital, Brest | ||
| Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis | NCT04370301 | Primary Myelofi... Secondary Myelo... | Cyclophosphamid... JAK Inhibitor Fludarabine Recombinant Gra... Melphalan Mycophenolate M... Peripheral Bloo... Tacrolimus Total-Body Irra... Computed Tomogr... Magnetic Resona... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col... Echocardiograph... Multigated Acqu... | 18 Years - | Fred Hutchinson Cancer Center | |
| Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation | NCT02311569 | Myeloproliferat... Primary Myelofi... Essential Throm... Polycythemia Ve... | Mirabegron | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer | NCT00296023 | Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | anti-thymocyte ... filgrastim therapeutic all... busulfan fludarabine pho... methotrexate tacrolimus nonmyeloablativ... peripheral bloo... | 18 Years - 75 Years | University of California, San Francisco | |
| Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy | NCT01428635 | Accelerated Pha... Blast Phase Chr... Chronic Phase C... Primary Myelofi... Thrombocytopeni... | Eltrombopag Ola... | 18 Years - | M.D. Anderson Cancer Center | |
| Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis | NCT01014546 | Essential Throm... Polycythemia Ve... Primary Myelofi... | Arsenic Trioxid... Ascorbic Acid Laboratory Biom... Pharmacological... | 19 Years - | Roswell Park Cancer Institute | |
| A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia | NCT04896112 | Acute Myeloid L... Primary Myelofi... Post-polycythem... Post-essential ... Polycythemia Ve... | LNK01002 | 18 Years - 99 Years | Lynk Pharmaceuticals Co., Ltd | |
| Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes | NCT06361641 | Myeloproliferat... Polycythemia Ve... Essential Throm... Primary Myelofi... | Monocytes signa... | 18 Years - | University Hospital, Angers | |
| Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence | NCT01178281 | Primary Myelofi... MPN-associated ... | Pomalidomide 0.... Placebo Pomalidomide | 18 Years - | Celgene | |
| Study of DISC-0974 in Participants With Myelofibrosis and Anemia | NCT05320198 | Myelofibrosis; ... Anemia Myelofibrosis Myelofibrosis D... Primary Myelofi... Post-essential ... | DISC-0974 | 18 Years - | Disc Medicine, Inc | |
| Assessment of Labile Plasma Iron (LPI) in Myelodysplastic Syndromes (MDS) and Primary Myelofibrosis | NCT01331603 | Myelodysplastic... Primary Myelofi... | 18 Years - | Wolfson Medical Center | ||
| Imatinib Mesylate in Treating Patients With Myelofibrosis | NCT00039416 | Chronic Myelomo... Essential Throm... Polycythemia Ve... Primary Myelofi... | imatinib mesyla... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder | NCT00722254 | Primary Myelofi... Primary Pulmona... Secondary Myelo... Pulmonary Arter... | 18 Years - | University of Utah | ||
| Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis | NCT01014546 | Essential Throm... Polycythemia Ve... Primary Myelofi... | Arsenic Trioxid... Ascorbic Acid Laboratory Biom... Pharmacological... | 19 Years - | Roswell Park Cancer Institute | |
| Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis | NCT03426969 | Primary Myelofi... Secondary Myelo... | Cyclophosphamid... Filgrastim Fludarabine Pho... Hematopoietic C... Melphalan Mycophenolate M... Tacrolimus Total-Body Irra... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis | NCT01014546 | Essential Throm... Polycythemia Ve... Primary Myelofi... | Arsenic Trioxid... Ascorbic Acid Laboratory Biom... Pharmacological... | 19 Years - | Roswell Park Cancer Institute | |
| Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders | NCT00397813 | Atypical Chroni... Chronic Myelomo... de Novo Myelody... Essential Throm... Myeloproliferat... Paroxysmal Noct... Polycythemia Ve... Polycythemia Ve... Primary Myelofi... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto... | Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Nonmyeloablativ... Peripheral Bloo... Total-Body Irra... | 50 Years - 75 Years | Fred Hutchinson Cancer Center | |
| Tipifarnib in Treating Patients With Advanced Hematologic Cancer | NCT00005967 | Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Myeloproliferative Neoplasms and Bone Structure | NCT01816022 | Polycythemia Ve... Thrombocythemia... Primary Myelofi... | 18 Years - | University of Southern Denmark | ||
| Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF | NCT01423851 | Primary Myelofi... Post-Polycythem... Post-Essential ... | NS-018 | 18 Years - | NS Pharma, Inc. | |
| Myeloproliferative Neoplastic Diseases Observatory From Brest | NCT02897297 | Polycythemia Ve... Essential Throm... Primary Myelofi... | - | University Hospital, Brest | ||
| Study of Canakinumab in Patients With Myelofibrosis | NCT05467800 | Primary Myelofi... Post-essential ... ET-MF Post-polycythem... PV-MF | Canakinumab | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder | NCT00722254 | Primary Myelofi... Primary Pulmona... Secondary Myelo... Pulmonary Arter... | 18 Years - | University of Utah | ||
| A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF | NCT01787552 | Primary Myelofi... Thrombocytosis Essential Throm... Polycythemia Ve... Myeloproliferat... Bone Marrow Dis... Hematologic Dis... Blood Coagulati... Blood Platelet ... Hemorrhagic Dis... | LDE225 INC424 | 18 Years - | Novartis | |
| Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) | NCT01236638 | Primary Myelofi... Post-Polycythem... Post-Essential ... | Momelotinib | 18 Years - | Sierra Oncology LLC - a GSK company | |
| PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis | NCT04054245 | Myelofibrosis T... Polycythemia Ve... Primary Myelofi... | LOXL2 Inhibitor... Quality-of-Life... Questionnaire A... | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) | NCT04173494 | Primary Myelofi... Post-polycythem... Post-essential ... | Momelotinib Placebo to matc... Danazol Placebo to matc... | 18 Years - | Sierra Oncology LLC - a GSK company | |
| Imatinib Mesylate in Treating Patients With Myelofibrosis | NCT00039416 | Chronic Myelomo... Essential Throm... Polycythemia Ve... Primary Myelofi... | imatinib mesyla... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis | NCT04370301 | Primary Myelofi... Secondary Myelo... | Cyclophosphamid... JAK Inhibitor Fludarabine Recombinant Gra... Melphalan Mycophenolate M... Peripheral Bloo... Tacrolimus Total-Body Irra... Computed Tomogr... Magnetic Resona... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col... Echocardiograph... Multigated Acqu... | 18 Years - | Fred Hutchinson Cancer Center | |
| Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib | NCT04884191 | Primary Myelofi... Post-Polycythem... Post- Essential... | Pacritinib | 18 Years - | CTI BioPharma | |
| A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence | NCT03194542 | Primary Myelofi... Anemia | Luspatercept | 18 Years - | Celgene | |
| Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia | NCT03195010 | Acute Biphenoty... Acute Lymphobla... Acute Myeloid L... B-Cell Non-Hodg... Chronic Lymphoc... Chronic Myeloge... Hematologic and... Hematopoietic C... Myelodysplastic... Primary Myelofi... Secondary Myelo... T-Cell Non-Hodg... Thrombocytopeni... Venous Thromboe... | Platelet Transf... Platelet Transf... | 18 Years - | Fred Hutchinson Cancer Center | |
| Myeloproliferative Neoplasms (MPNs) Patient Registry | NCT02760238 | Primary Myelofi... Polycythemia Ve... Essential Throm... Mastocytosis Leukemia, Myelo... Leukemia, Myelo... Chronic Eosinop... Myelodysplastic... Neoplasms Leukemia, Myelo... | Observational | - | University Health Network, Toronto | |
| LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis | NCT02098161 | Polycythemia Ve... Primary Myelofi... Secondary Myelo... | Laboratory Biom... Questionnaire A... Smac Mimetic LC... | 18 Years - | M.D. Anderson Cancer Center | |
| A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis | NCT00631462 | Myelofibrosis | TG101348 | 18 Years - | TargeGen | |
| A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment | NCT04576156 | Myelofibrosis | Imetelstat Best Available ... | 18 Years - | Geron Corporation | |
| A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i) | NCT06343805 | Primary Myelofi... Post-Essential ... Post-Polycythem... PMF PPV-MF PET-MF | AJ1-11095 | 18 Years - | Ajax Therapeutics, Inc. | |
| Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT | NCT02728700 | Adult Hodgkin L... Adult Myelodysp... Blast Phase Chr... Childhood Chron... Childhood Hodgk... Childhood Myelo... Chronic Phase C... Myelofibrosis Primary Myelofi... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Chron... Refractory Chro... Refractory Non-... | Allogeneic Hema... Laboratory Biom... Mycophenolate M... Sirolimus | 3 Years - 30 Years | Stanford University | |
| Myeloproliferative Neoplasms (MPNs) Patient Registry | NCT02760238 | Primary Myelofi... Polycythemia Ve... Essential Throm... Mastocytosis Leukemia, Myelo... Leukemia, Myelo... Chronic Eosinop... Myelodysplastic... Neoplasms Leukemia, Myelo... | Observational | - | University Health Network, Toronto | |
| Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation | NCT04339101 | Acute Leukemia Hematologic and... Myelodysplastic... Primary Myelofi... Secondary Myelo... | Fludarabine Itacitinib Adip... Melphalan Quality-of-Life... Questionnaire A... Sirolimus Tacrolimus | 18 Years - 75 Years | City of Hope Medical Center | |
| Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation | NCT02311569 | Myeloproliferat... Primary Myelofi... Essential Throm... Polycythemia Ve... | Mirabegron | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML | NCT00069992 | Chronic Myelopr... Leukemia Myelodysplastic... | Total Body Irra... Fludarabine Campath 1H | - | Baylor College of Medicine | |
| To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) | NCT04551066 | Myelofibrosis Primary Myelofi... Post Essential ... Post Polycythem... | parsaclisib ruxolitinib placebo | 18 Years - | Incyte Corporation | |
| Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders | NCT00397813 | Atypical Chroni... Chronic Myelomo... de Novo Myelody... Essential Throm... Myeloproliferat... Paroxysmal Noct... Polycythemia Ve... Polycythemia Ve... Primary Myelofi... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto... | Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Nonmyeloablativ... Peripheral Bloo... Total-Body Irra... | 50 Years - 75 Years | Fred Hutchinson Cancer Center | |
| CINC424A2X01B Rollover Protocol | NCT02386800 | Primary Myelofi... Polycythemia Ve... Graft Versus Ho... Acute Myeloid L... Thalassemia | ruxolitinib panobinostat | 1 Month - | Novartis | |
| An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib | NCT03952039 | Primary Myelofi... Post-Polycythem... Myelofibrosis | FEDRATINIB Best Available ... | 18 Years - | Celgene | |
| Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis | NCT04709458 | Myelofibrosis Acute Myelogeno... | TBX-2400 | 18 Years - | Taiga Biotechnologies, Inc. | |
| Real World Evidence of Fedratinib Effectiveness in MF | NCT05883904 | Primary Myelofi... Post-polycythem... Post-essential ... | Fedratinib | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis | NCT06073847 | Primary Myelofi... Post-polycythem... Post-essential ... | Fedratinib | 19 Years - | Bristol-Myers Squibb | |
| Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients | NCT04243122 | Myeloproliferat... Essential Throm... JAK2 Mutation Polycythemia Ve... Primary Myelofi... Venous Thromboe... | Apixaban 2.5 MG... Aspirin 81 mg | 18 Years - | Ottawa Hospital Research Institute | |
| A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis | NCT02584777 | Primary Myelofi... | Pacritinib | 18 Years - | Takeda | |
| MPN-RC 118 AVID200 in Myelofibrosis | NCT03895112 | Primary Myelofi... Post-essential ... Post-polycythem... Post ET MF Post PV MF | AVID200 | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation | NCT04339101 | Acute Leukemia Hematologic and... Myelodysplastic... Primary Myelofi... Secondary Myelo... | Fludarabine Itacitinib Adip... Melphalan Quality-of-Life... Questionnaire A... Sirolimus Tacrolimus | 18 Years - 75 Years | City of Hope Medical Center | |
| Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis | NCT02871323 | Polycythemia Ve... Primary Myelofi... | Durvalumab Laboratory Biom... | 18 Years - | Northwestern University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
